Innate Pharma (IPHA) — Cash Flow Reinvestment Rate
Innate Pharma (IPHA) has a Cash Flow Reinvestment Rate of 0.09x as of June 2024, reinvesting $283.00K (capex $283.00K ) from operating cash flow of $3.04 Million. See Innate Pharma free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Innate Pharma Cash Flow Reinvestment Rate (2006–2019)
Historical reinvestment intensity for Innate Pharma across 4 annual periods. For the full cash flow conversion analysis, see Innate Pharma (IPHA) cash conversion ratio.
Annual Cash Flow Reinvestment Rate for Innate Pharma (2006–2019)
Year-by-year capital reinvestment analysis for Innate Pharma. See Innate Pharma free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2019 | 3.65x | $127.52 Million | $34.92 Million | $65.40 Million | ▲ +469.8% |
| 2015 | 0.64x | $133.24 Million | $207.91 Million | $7.40 Million | ▲ +2484.4% |
| 2011 | 0.02x | $322.00K | $12.99 Million | $322.00K | ▼ -98.8% |
| 2006 | 2.09x | $752.00K | $360.00K | $752.00K | — |